<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952756</url>
  </required_header>
  <id_info>
    <org_study_id>NCKUH-10103043/BR-100-134</org_study_id>
    <nct_id>NCT01952756</nct_id>
  </id_info>
  <brief_title>Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)</brief_title>
  <official_title>Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health, Executive Yuan, R.O.C. (Taiwan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The number and function of circulating endothelial progenitor cells (EPCs) are inversely&#xD;
           associated with coronary risk factors and atherosclerotic diseases such as PAOD.&#xD;
&#xD;
        2. This double-blind, randomized, placebo-controlled trial to evaluate the effects of&#xD;
           cilostazol on human early EPCs and angiogenesis as well as the potential mechanisms of&#xD;
           action in patients with mild-to-moderate PAOD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. titration of drugs&#xD;
&#xD;
             1. run-in period: eligible subjects are screened and baseline blood samples are&#xD;
                obtained&#xD;
&#xD;
             2. study period: 12 weeks&#xD;
&#xD;
                  -  24 subjects with cilostazol and 20 subjects with dummy placebo&#xD;
&#xD;
                  -  On the first day after the end of the study period, the follow-up data are&#xD;
                     obtained by the same procedure&#xD;
&#xD;
             3. blood sampling and measurement of serum biomarkers&#xD;
&#xD;
                  -  obtained from peripheral veins in all study subjects at the run-in period and&#xD;
                     the end of the treatment period of the study&#xD;
&#xD;
                  -  sent for isolation, cell culture, and assays of human EPCs&#xD;
&#xD;
                  -  also stored for enzyme-linked immunosorbent assay (Stromal cell derived&#xD;
                     factor-alfa1, adiponectin, soluble thrombomodulin, vascular endothelial growth&#xD;
                     factor)&#xD;
&#xD;
        2. assays of human EPCs&#xD;
&#xD;
             1. colony formation by EPCs&#xD;
&#xD;
             2. quantification of EPCs and apoptotic endothelial cells&#xD;
&#xD;
             3. chemotactic motility, proliferation/viability and apoptosis assays&#xD;
&#xD;
        3. collateral vessels formation and distal run-off assessed by dual-energy multi-slice&#xD;
           computed tomography angiography&#xD;
&#xD;
        4. echocardiographic examinations to evaluate left ventricular functions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating EPCs Number</measure>
    <time_frame>3 months</time_frame>
    <description>Peripheral blood mononuclear cells (one million cells in each) are suspended in 100 µL phosphate-buffered saline and incubated for 30 min with monoclonal antibodies against human peridinin chlorophyll protein-conjugated cluster of differentiation antigen-45, phycoerythrin-conjugated anti-human cluster of differentiation antigen-34 antibody and anti-human kinase insert domain receptor (KDR) antibody conjugated with Alexa Flour 647. Cells are washed and analyzed on a FACSCalibur flow cytometer with 100,000 events in the lymphocyte gate. EPCs, which are defined as negative for cluster of differentiation antigen-45 and positive for cluster of differentiation antigen-34 and KDR. Based on the peripheral blood mononuclear cell counts, the absolute number of circulating EPCs/µL is calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colony Formation by EPCs</measure>
    <time_frame>3 months</time_frame>
    <description>Peripheral blood mononuclear cells are isolated by density gradient centrifugation according to standard protocols. After centrifugation, cells are washed, resuspended in M199 medium supplemented with 20% (vol/vol) fetal bovine serum, 10 ng/ml vascular endothelial growth factor, 2 ng/ml basic-fibroblast growth factor, 10 ng/ml epidermal growth factor and 2 ng/ml insulin growth factor, and cultured in 24-well plates coated with human fibronectin for 7 days. EPCs cells are confirmed by uptake of acetyl-low density lipoprotein and lectin and by the expression of EPC markers. Cells are harvested after 7 days, fixed and stained with crystal violet reagent. The colony densities are quantified with an Olympus microscope at 100-fold magnification using an imaging measurement software.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Viability (Proliferation) of EPCs</measure>
    <time_frame>3 months</time_frame>
    <description>250,000 cells are seeded in each well of a 96-well plate and the cells are added with 200 μl of the culture medium and incubated at 37°C. Medium change is performed 3 days later. On 7th day, the plate is then re-incubated with 100 μl fresh medium and additional 50 μl of 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2 Hydrogen-Tetrazolium-5-Carboxanilide reagent, and further incubated in dark at 37°C for 4 h. After incubation, the orange colored complex formed is read at 450 nm using a microplate reader with a 450 nm reference filter.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Peripheral Arterial Diseases</condition>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One tablet (100 mg) twice per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dummy Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet twice per day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>One tablet (100 mg) twice per day for 12 weeks</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>Pletaal (brand name)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dummy Placebo</intervention_name>
    <description>One tablet twice per day for 12 weeks</description>
    <arm_group_label>Dummy Placebo</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ankle-brachial index (ABI) less than 0.9 in one or both legs but no obvious symptoms&#xD;
             of intermittent claudication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  obvious symptoms of intermittent claudication&#xD;
&#xD;
          -  severe PAD (Fontaine grading &gt; 3) or critical limb ischemia in at least one leg&#xD;
&#xD;
          -  severe liver dysfunction (transaminases &gt;10 times of upper normal limit, history of&#xD;
             liver cirrhosis, or hepatoma)&#xD;
&#xD;
          -  &gt; stage 4 chronic kidney disease (end-stage renal disease with chronic dialysis not&#xD;
             excluded)&#xD;
&#xD;
          -  left ventricular ejection fraction &lt;50% by echocardiography&#xD;
&#xD;
          -  documented active malignancy&#xD;
&#xD;
          -  chronic inflammatory disease&#xD;
&#xD;
          -  planned coronary intervention or endovascular therapy or bypass surgery within 3&#xD;
             months&#xD;
&#xD;
          -  known drug allergy history for cilostazol&#xD;
&#xD;
          -  current use of cilostazol or any other cAMP-elevator&#xD;
&#xD;
          -  premenopausal women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ting-Hsing Chao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Chao TH, Tseng SY, Li YH, Liu PY, Cho CL, Shi GY, Wu HL, Chen JH. A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clin Sci (Lond). 2012 Aug 1;123(3):147-59. doi: 10.1042/CS20110432.</citation>
    <PMID>22339730</PMID>
  </reference>
  <reference>
    <citation>Biscetti F, Pecorini G, Straface G, Arena V, Stigliano E, Rutella S, Locatelli F, Angelini F, Ghirlanda G, Flex A. Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. Int J Cardiol. 2013 Aug 10;167(3):910-6. doi: 10.1016/j.ijcard.2012.03.103. Epub 2012 Apr 2.</citation>
    <PMID>22473072</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>September 21, 2013</study_first_submitted>
  <study_first_submitted_qc>September 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <last_update_submitted>July 16, 2014</last_update_submitted>
  <last_update_submitted_qc>July 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cilostazol</keyword>
  <keyword>endothelial progenitor cells</keyword>
  <keyword>vasculogenesis</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>peripheral arterial disease</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

